Martinez A, Goffinet D R, Donaldson S S, Bagshaw M A, Kaplan H S
Int J Radiat Oncol Biol Phys. 1985 Jan;11(1):123-8. doi: 10.1016/0360-3016(85)90370-0.
Combined modality treatment was given in nine patients of osteogenic sarcoma wherein the tumor was unresectable because of location or amputation was refused. This alternative to massive surgery comprised hypofractionated irradiation, intra-arterial infusion of the radiosensitizer 5'-bromodeoxyuridine (BUdR) and adjuvant systemic chemotherapy. Local control was achieved in seven of the nine patients. Four survived, all without evidence of disease at 6, 7.1, 8.8, and 10.5 years after completion of irradiation. Pulmonary metastases developed in six patients--of whom one survives, following high-dose pulmonary irradiation and additional chemotherapy. Significant soft-tissue injury occurred in five patients. On the basis of our experience, we believe that new approaches using modifications of external beam irradiation with different fractionation schedules or better radiosensitizing compounds may hold promise for patients with non-resectable osteosarcoma.
对9例骨肉瘤患者采用了综合治疗模式，这些患者因肿瘤位置原因无法切除或拒绝截肢。这种替代大规模手术的方法包括超分割放疗、动脉内输注放射增敏剂5'-溴脱氧尿苷（BUdR）和辅助全身化疗。9例患者中有7例实现了局部控制。4例存活，在放疗结束后6年、7.1年、8.8年和10.5年时均无疾病迹象。6例患者发生了肺转移，其中1例在接受高剂量肺部放疗和额外化疗后存活。5例患者出现了明显的软组织损伤。根据我们的经验，我们认为采用不同分割方案的外照射修改或更好的放射增敏化合物的新方法可能对不可切除骨肉瘤患者有希望。
